Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies

AbD Serotec will use proprietary technology to generate antibodies against novel research targets provided by Sigma-Aldrich

28-Feb-2008

Sigma-Aldrich and MorphoSys AG announced a collaboration agreement to design, produce and distribute unique recombinant research antibodies using MorphoSys's proprietary HuCAL GOLD(R) technology. MorphoSys's AbD Serotec unit will develop and qualify unique antibodies from MorphoSys's proprietary HuCAL GOLD library against a committed number of targets identified and supplied by Sigma-Aldrich.

"We are very excited about the potential of this partnership," said Dr. David Smoller, president of Sigma-Aldrich's Research Biotech business unit. "HuCAL-based recombinant antibody technology will allow researchers access to antibody content not available through standard antibody generation technologies. In conjunction with Sigma-Aldrich's standard content generation capabilities, this powerful technology is expected to allow the community to reach its goal of a binder for every gene and one-day even protein in the human body."

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous